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VEGF-related polymorphisms identified by GWAS and risk
for major depression
T Xie1,7, MG Stathopoulou1,7, F de Andrés2, G Siest1, H Murray3, M Martin4, J Cobaleda5, A Delgado2, J Lamont3, E Peñas-LIedó2,
A LLerena2,6 and S Visvikis-Siest1
Depression is a common, severe, disabling mental disease that affects millions of people of all ages worldwide. Various studies have
shown that neurotrophic/growth factors have a key role in depression and, more specifically, vascular endothelial growth factor
(VEGF) is implicated in the pathogenesis of depression. The purpose of this study was to investigate the potential links between
four VEGF-related single-nucleotide polymorphisms (SNPs), previously identified through a genome-wide association study (GWAS)
and depression. The direct effects and epistatic interactions of the four VEGF-related SNPs (rs10738760, rs6921438, rs6993770 and
rs4416670) on depression were investigated through a case–control study including 437 individuals diagnosed with depression and
477 healthy volunteers as controls. Gender, age and body mass index influence was additionally analyzed. The SNP rs4416670 was
associated with increased risk for depression (OR: 1.60, P: 0.010). This result demonstrates the existence of relationships between
VEGF genetic determinants and depression. This novel association reveals new molecular mechanisms suggesting the potential role
of VEGF in depression development that could help to promote a personalized prediction for this severe common disease.
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INTRODUCTION
Depression is a common, severe, disabling mental disease that
affects millions of people of all ages. Depression is also a leading
cause of mortality worldwide, as it can lead to suicide and causes a
high burden for patients, their families and the healthcare system.
In addition population studies have shown that women are
affected by depression more than men, but no study clearly
explains the causes of this observation.1
Various studies have shown that neurotrophic/growth factors are
key factors in depression. One of the most important is brain-
derived neurotrophic factor (BDNF) and several studies have
focused also on vascular endothelial growth factor (VEGF), which
is recognized as a major inducer of angiogenesis and
vasculogenesis.2 However, VEGF is a multifunctional molecule that
has effects also in the central nervous system3 VEGF has been
shown to have effects on specific areas of the brain, such as
hippocampus,4 and neurogenesis has been shown to be stimulated
in vitro and in vivo by VEGF.5 Proinflammatory cytokines have been
implicated in depression,6,7 while VEGF is regulated by proin-
flammatory cytokines in depression.8 Taking together the above
information, it has been suggested that interaction between VEGF
and proinflammatory cytokines could influence depression and/or
the potential efficacy of the treatments with antidepressants.9
Numerous studies have investigated the peripheral/serum
levels of VEGF in depressed patients and compared them with a
control group of healthy subjects; however the results are unclear
and ambiguous yet, due to differences in the populations studied.
Increased VEGF levels have been observed in depressed patients
when compared to healthy controls,10 but no differences have
been reported in other studies.11,12 In contrast to these results,
one study revealed a decrease in plasma and serum VEGF levels in
depressed patients.13 However, environment factors like gender,
age and body mass index (BMI) have not been adequately
assessed in the aforementioned association studies and they
could potentially explain the controversy observed.14
Given the associations between VEGF and depression, a common
genetic regulation could be hypothesized. Depression is a complex
disease, and it has a heritable background.15 Few studies have
focused on VEGF gene polymorphisms role in depression. Among
them, Viikki et al.16 have shown that one VEGF polymorphism,
rs699947, is associated with treatment resistant depression.
Recently we have identified through a genome-wide association
study (GWAS) four single-nucleotide polymorphisms (SNPs) in three
chromosomes, which explain almost 50% of the inter-individual
variability of VEGF circulating levels.17 Therefore, we hypothesize
that these strong genetic determinants of VEGF could also be
implicated in depression. Thus, the aim of this study was to
investigate the direct effects and epistatic interactions of the 4
VEGF-related polymorphisms (rs10738760, rs6921438, rs6993770
and rs4416670) on depression by a case–control study, aiming to
detect potential genetic biomarkers between VEGF and depression.
MATERIALS AND METHODS
Population
Four hundred thirty seven unrelated Spanish Caucasian patients diagnosed
with depressive disorders (132 males/305 females, mean age: 51.49 ± 14.04
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years, mean BMI: 28.56±6.56 kg/m2) who were attending a Mental Health
Centre, were included. The descriptions of depressive disorders and any
psychiatric condition, in which depression was a primary symptom and
therefore were under antidepressant treatment, were taken from the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV criteria).18 A
group control of 477 (187 males/290 females, mean age: 66.24±15.01 years,
mean BMI: 29.33±11.41 kg/m2) Caucasian healthy volunteers from the same
geographical region was also studied. The individuals of the control group
were selected by psychiatrists who performed a mental and physical revision,
as well as revised medical history to check health state, in order to consider
about inclusion as healthy individuals. First-degree relatives were also
assessed by psychiatrists regarding potential psychiatric disorders. However,
to avoid familial stratification issues, only unrelated individuals have been
included in the control group. Healthy volunteers with a previous history of
adverse drug effects and those with any drug intake in the 2 weeks before
the study were excluded from participation in the study. Women who
reported or suspected pregnancy were also excluded from the study.
Written informed consent was obtained for all the participants of the
study, and the study was performed according to the Helsinki Declaration.
This study was approved by the Ethical Committee of Extremadura
University Hospital, Badajoz, Spain and of Navarra Health Care System,
Pamplona, Spain.
Genotyping
Five milliliters of peripheral blood were drawn in a tube with EDTA, and
then the genomic DNA was isolated with the QIAGEN Blood DNA isolation
kit (Qiagen, Hilden, Germany) and evaluated for integrity and concentra-
tion through 1% agarose electrophoresis and spectrophotometry. The
SNPs rs6921438, rs4416670, rs6993770 and rs10738760 were genotyped
using the competitive allele-specific PCR (KASP) chemistry coupled with a
FRET-based genotyping system (http://www.lgcgroup.com/services/geno
typing/#.VmQwfoR6GFI), and genotyping was confirmed by Randox
Laboratories (Crumlin, UK; Evidence Investigator) using an assay based
on a combination of multiplex PCR and biochip array hybridization.
Statistical analysis
Hardy–Weinberg equilibrium was tested using a χ2-test. The analysis was
carried out using the Generalized Multifactor Dimensionality Reduction
(GMDR0.9) software (University of Alabama, Birmingham, AL, USA), which is
a nonparametric and genetic model-free19 alternative to linear or logPage
Page 6/istic regression for detecting and characterizing nonlinear interac-
tions among discrete genetic and environmental attributes. Age, gender and
BMI were used as co-variables. The score of co-variables was calculated by
logistic regression, and then the analysis was performed using the GMDR.
Epistatic interactions were assessed only between SNPs with significant
direct effects and all the others. The SNPs analyzed are located in different
chromosomes; therefore haplotype analysis was not performed as no
linkage between SNPs occurs. Direct associations were tested at two-sided
Po0.012 (corrected for 4 tests) and epistatic interactions were tested at
two-sided Po0.05/number of final interaction tests.
RESULTS
The characteristics of the SNPs are presented in Table 1. Hardy–
Weinberg equilibrium was not observed in the SNP rs4416670 in
the group of cases due to significant disagreement found
between expected and observed frequencies, thus indicating a
difference in the frequency of this SNP in depression patients.
Associations of the SNPs in cases-controls
Among the four SNPs studied, only the rs4416670 was signifi-
cantly associated with depression. As shown in Tables 2A and 2B,
this SNP was associated with an increased risk for depression (OR:
1.60; Table 2A), while the minor allele C was more frequent in
patients (Table 2B). No association with depression was found for
the other three SNPs.
Epistatic interactions between the 4 SNPs and depression
As only one SNP (rs4416670) was directly associated with
depression, we have assessed only the epistatic interactions
involving this SNP. The significance cut off value was set at P
0.05/3 (3 interaction tests) = 0.016.
No significant interaction was identified.
DISCUSSION
In this study, we identified links between VEGF-related genetic
polymorphisms and depression. More precisely, one SNP
(rs4416670) related to VEGF levels17 was associated with increased
risk for depression. The minor allele of this polymorphism has
been previously associated with decreased VEGF levels.17 As this
polymorphism has a very high frequency (almost 50%), the effect
of the minor allele can affect a large percentage of the population,
thus having an important impact for public health.
Several studies revealed that proinflammatory cytokines are
implicated in the etiology of depression.6,20 Miller et al.20 have
underlined the relationship between proinflammatory cytokines
and depression in individuals with disorders that include chronic
inflammation. We have previously shown that in supposed healthy
individuals the C allele of rs4416670 was positively associated with
L-selectin mRNA, and that VEGF145 mRNA positively regulated
L-selectin expression.21 At the same time, L-selectin has been
shown to correlate with mental diseases such as the pathogenesis
of schizophrenia22 and the severity of panic disorder,23 thus
indicating that this molecule can play a significant role in these
conditions. Despite these associations have not been demon-
strated yet in patients with depression, based on our results, we
could propose the hypothesis that L-selectin could be implicated
in depression development, and this effect could be additionally
dependent on the genotype of rs4416670. The presence of the C











6 rs4416670 C 0.469 0.035 0.468 0.579
6 rs6921438 A 0.408 0.496 0.454 0.606
8 rs6993770 T 0.356 0.412 0.340 0.663
9 rs10738760 A 0.463 0.076 0.470 0.769
Abbreviations: Chr, chromosome; HWE, Hardy–Weinberg equilibrium; MAF,
minor allele frequency; SNP, single-nucleotide polymorphism.
Table 2A. Associations between VEGF-related with depression
Marker Allele
Major/minor
OR (95% CI) P Chi-square
rs4416670 T/C 1.60 (1.03–2.46) 0.010 4.38 (P= 0.036)
Abbreviations: CI, confidence interval; OR, odds ratio; VEGF, vascular
endothelial growth factor.
Table 2B. Alleles investigation for the rs4416670 in patients versus
controls






CC 56.39 47.00 1
TC 119.36 109.75 1
TT 41.93 58.79 0
aProbability of being affected. b0—control; 1—patient.
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allele of this SNP is increasing expression of L-selectin, which could
indicate an increased risk for depression. This hypothesis should
be tested in future studies.
Concerning the role of VEGF, the C allele of the rs4416670
(currently linked with increased risk of depression) was associated
with decreased levels of VEGF.17 Therefore, our present findings
are consistent with a previous study showing a negative
correlation between serum VEGF concentration and scores on a
widely used diagnostic measure of depression, the Hamilton
Depression Rating Scale.12 Furthermore, a significantly decrease in
plasma VEGF has been shown in individuals exposed to a stressful
military training and environment.24 Thus, it is possible that the
present findings could be also explained in the frame of the
diathesis-stress model of depression,25,26 making individuals
carrying this VEGF SNP more likely to develop depression due to
a significant downregulation of VEGF blood levels during or after
exposure to stress, and/or to a greater vulnerability to stress.
Another previous study also showed that the subset of patients
who responded to antidepressant treatment were those with
decreased plasma VEGF levels.27 Therefore, future studies will
have to test whether these SNPs show less tolerance to
environmental stress, and/or decreases in plasma VEGF levels
and whether they are overrepresented among depressive patients
who respond to antidepressant treatment contrary to those who
do not respond.
In conclusion, to our knowledge, this is the first study that has
assessed the common genetic regulation between VEGF and
depression with important original results that reveal novel
molecular mechanisms for this common, severe and disabling
mental disease. The identification of SNPs that may predict
susceptibility to depression and/or response to treatment can
have important implication in clinical practice. Further research on
these mechanisms involved in depression development and
response to treatment, as well as the functional role of these
SNPs could allow the implementation of these findings in
personalized risk prediction and hopefully targeted treatment of
depression.
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